104 related articles for article (PubMed ID: 25738706)
1. Ribavirin as a tri-targeted antitumor repositioned drug.
De la Cruz-Hernandez E; Medina-Franco JL; Trujillo J; Chavez-Blanco A; Dominguez-Gomez G; Perez-Cardenas E; Gonzalez-Fierro A; Taja-Chayeb L; Dueñas-Gonzalez A
Oncol Rep; 2015 May; 33(5):2384-92. PubMed ID: 25738706
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
Kikuchi J; Takashina T; Kinoshita I; Kikuchi E; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Marquez VE; Nishimura M; Dosaka-Akita H
Lung Cancer; 2012 Nov; 78(2):138-43. PubMed ID: 22925699
[TBL] [Abstract][Full Text] [Related]
3. Repurposing the FDA-Approved Antiviral Drug Ribavirin as Targeted Therapy for Nasopharyngeal Carcinoma.
Huq S; Casaos J; Serra R; Peters M; Xia Y; Ding AS; Ehresman J; Kedda JN; Morales M; Gorelick NL; Zhao T; Ishida W; Perdomo-Pantoja A; Cecia A; Ji C; Suk I; Sidransky D; Brait M; Brem H; Skuli N; Tyler B
Mol Cancer Ther; 2020 Sep; 19(9):1797-1808. PubMed ID: 32606016
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.
Nakagawa S; Sakamoto Y; Okabe H; Hayashi H; Hashimoto D; Yokoyama N; Tokunaga R; Sakamoto K; Kuroki H; Mima K; Beppu T; Baba H
Oncol Rep; 2014 Feb; 31(2):983-8. PubMed ID: 24337160
[TBL] [Abstract][Full Text] [Related]
5. Preclinical efficacy of ribavirin in SHH and group 3 medulloblastoma.
Huq S; Kannapadi NV; Casaos J; Lott T; Felder R; Serra R; Gorelick NL; Ruiz-Cardozo MA; Ding AS; Cecia A; Medikonda R; Ehresman J; Brem H; Skuli N; Tyler BM
J Neurosurg Pediatr; 2021 Feb; 27(4):482-488. PubMed ID: 33545678
[TBL] [Abstract][Full Text] [Related]
6. Growth inhibition and transcriptional effects of ribavirin in lymphoma.
Dominguez-Gomez G; Cortez-Pedroza D; Chavez-Blanco A; Taja-Chayeb L; Hidalgo-Miranda A; Cedro-Tanda A; Beltran-Anaya F; Diaz-Chavez J; Schcolnik-Cabrera A; Gonzalez-Fierro A; Dueñas-Gonzalez A
Oncol Rep; 2019 Sep; 42(3):1248-1256. PubMed ID: 31322273
[TBL] [Abstract][Full Text] [Related]
7. Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
Woo J; Kim HY; Byun BJ; Chae CH; Lee JY; Ryu SY; Park WK; Cho H; Choi G
Bioorg Med Chem Lett; 2014 Jun; 24(11):2486-92. PubMed ID: 24767850
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of eIF4E cooperates with chemotherapy and immunotherapy in renal cell carcinoma.
Cao J; Sun X; Zhang X; Chen D
Clin Transl Oncol; 2018 Jun; 20(6):761-767. PubMed ID: 29086249
[TBL] [Abstract][Full Text] [Related]
9. Antiviral Drug Ribavirin Targets Thyroid Cancer Cells by Inhibiting the eIF4E-β-Catenin Axis.
Shen X; Zhu Y; Xiao Z; Dai X; Liu D; Li L; Xiao B
Am J Med Sci; 2017 Aug; 354(2):182-189. PubMed ID: 28864377
[TBL] [Abstract][Full Text] [Related]
10. Enhancer of zeste homolog 2 is overexpressed and contributes to epigenetic inactivation of p21 and phosphatase and tensin homolog in B-cell acute lymphoblastic leukemia.
Chen J; Li J; Han Q; Sun Z; Wang J; Wang S; Zhao RC
Exp Biol Med (Maywood); 2012 Sep; 237(9):1110-6. PubMed ID: 22956625
[TBL] [Abstract][Full Text] [Related]
11. S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition.
Hayden A; Johnson PW; Packham G; Crabb SJ
Breast Cancer Res Treat; 2011 May; 127(1):109-19. PubMed ID: 20556507
[TBL] [Abstract][Full Text] [Related]
12. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep).
Cheng LL; Itahana Y; Lei ZD; Chia NY; Wu Y; Yu Y; Zhang SL; Thike AA; Pandey A; Rozen S; Voorhoeve PM; Yu Q; Tan PH; Bay BH; Itahana K; Tan P
Clin Cancer Res; 2012 Aug; 18(15):4201-12. PubMed ID: 22675170
[TBL] [Abstract][Full Text] [Related]
13. Targeting eIF4E inhibits growth, survival and angiogenesis in retinoblastoma and enhances efficacy of chemotherapy.
Wang G; Li Z; Li Z; Huang Y; Mao X; Xu C; Cui S
Biomed Pharmacother; 2017 Dec; 96():750-756. PubMed ID: 29049978
[TBL] [Abstract][Full Text] [Related]
14. EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells.
Katona BW; Liu Y; Ma A; Jin J; Hua X
Cancer Biol Ther; 2014; 15(12):1677-87. PubMed ID: 25535899
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the antiproliferative effects of 3-deazaneoplanocin A in combination with standard anticancer agents in rhabdoid tumor cell lines.
Unland R; Borchardt C; Clemens D; Kool M; Dirksen U; Frühwald MC
Anticancer Drugs; 2015 Mar; 26(3):301-11. PubMed ID: 25415657
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic regulation of cell adhesion and communication by enhancer of zeste homolog 2 in human endothelial cells.
Dreger H; Ludwig A; Weller A; Stangl V; Baumann G; Meiners S; Stangl K
Hypertension; 2012 Nov; 60(5):1176-83. PubMed ID: 22966008
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of eIF4E signaling by ribavirin selectively targets lung cancer and angiogenesis.
Tan H; He L; Cheng Z
Biochem Biophys Res Commun; 2020 Aug; 529(3):519-525. PubMed ID: 32736668
[TBL] [Abstract][Full Text] [Related]
18. The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer.
Ding M; Zhang H; Li Z; Wang C; Chen J; Shi L; Xu D; Gao Y
Clin Exp Pharmacol Physiol; 2015 May; 42(5):458-64. PubMed ID: 25739318
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of eukaryotic translation initiation factor 4E is effective against chemo-resistance in colon and cervical cancer.
Xi C; Wang L; Yu J; Ye H; Cao L; Gong Z
Biochem Biophys Res Commun; 2018 Sep; 503(4):2286-2292. PubMed ID: 29959920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]